Lineage Cell Therapeutics, Inc. Quarterly Operating Lease, Payments in USD from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Operating Lease, Payments history and growth rate from Q1 2019 to Q1 2024.
  • Lineage Cell Therapeutics, Inc. Operating Lease, Payments for the quarter ending March 31, 2024 was $302K, a 4.13% decline year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Operating Lease, Payments for 2023 was $1.13M, a 7.83% increase from 2022.
  • Lineage Cell Therapeutics, Inc. annual Operating Lease, Payments for 2022 was $1.05M, a 12% increase from 2021.
  • Lineage Cell Therapeutics, Inc. annual Operating Lease, Payments for 2021 was $935K, a 31% decline from 2020.
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $302K -$13K -4.13% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q1 2023 $315K +$60K +23.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q1 2022 $255K +$47K +22.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $208K -$190K -47.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q1 2020 $398K +$67K +20.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q1 2019 $331K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.